Tag: Genesis MedTech

Advancing Healthcare Access: Genesis MedTech Teams Up with Silk Road Medical to Serve Patients affected by Carotid Artery Disease in China

WUXI, China, March 7, 2024 /PRNewswire/ — Silk Road Medical (NASDAQ: SILK), a medical device company based in California USA and Genesis MedTech Group have signed an exclusive distribution agreement to introduce the TCAR® core products, ENROUTE® Transcarotid Neuroprotection System and…

Genesis MedTech Completes Enrollment in its United States Early Feasibility Study Utilizing the J-Valve™ Transfemoral System for Patients with Severe Aortic Regurgitation

BURLINGAME, Calif., Feb. 5, 2024 /PRNewswire/ — Genesis MedTech, a leading medical device company, today announced the completion of enrollment in its United States Early Feasibility Study (EFS) using its dedicated transcatheter aortic valve replacement (TAVR) system, J-Valve™ Transfemoral (TF) System. Finalizing the […]

Genesis MedTech initiates enrolment in its North American Early Feasibility Study using the J-Valve™ Transfemoral System for patients with severe aortic regurgitation

BURLINGAME, Calif., Oct. 23, 2023 /PRNewswire/ — Genesis MedTech, a leading medical device company, today announced initiation of enrolment in its North American Early Feasibility Study using its dedicated TAVR system, J-Valve™ Transfemoral (TF) System. The procedure was successfully performed by Dr. Dean Kereiakes, […]

Genesis MedTech announces FDA Breakthrough Device designation for the J-Valve™ Transfemoral System

BURLINGAME Calif., Aug. 1, 2023 /PRNewswire/ — Genesis MedTech, a leading medical device company, today announced that its J-Valve™ Transfemoral (TF) System has been granted Breakthrough Device designation by the U.S. Food and Drug Administration (FDA). This innovative heart valve has been granted […]

CHOCOLATE TOUCH®, NEXT-GENERATION DRUG-COATED ANGIOPLASTY BALLOON FOR THE TREATMENT OF PERIPHERAL ARTERIAL DISEASE RECEIVES FDA APPROVAL

SINGAPORE, Nov. 11, 2022 /PRNewswire/ — Genesis MedTech Group announced today that the Food and Drug Administration (FDA) has approved the Chocolate Touch® Drug-coated Balloon PTA Catheter, developed by TriReme Medical LLC, for the treatment of patients with peripheral artery disease in […]

SERIAL INNOVATOR, EITAN KONSTANTINO JOINS GENESIS MEDTECH AS CTO OF VASCULAR INTERVENTIONS FRANCHISE

SINGAPORE, Jan. 7, 2022 /PRNewswire/ — Genesis MedTech Group (Genesis or Group) has appointed Dr. Eitan Konstantino (Eitan) as CTO of Vascular Interventions to propel Genesis’ technology innovation within the neurovascular, cardiovascular and peripheral vascular spaces. His role will include developing and implementing the […]

Genesis MedTech Acquires World-first Drug-coated Balloon Technology with Next-generation Angioplasty Architecture for the Treatment of Peripheral Vascular Diseases

– Provides patients suffering from peripheral vascular diseases a safer and more effective treatment than traditional balloon angioplasty – DCB to become the future standard of care for superficial femoral artery treatment – Fast growing global market with estimated 13% […]